Short Interest in Aardvark Therapeutics, Inc. (NASDAQ:AARD) Declines By 42.1%

Aardvark Therapeutics, Inc. (NASDAQ:AARD) saw a significant decrease in short interest in June. As of June 30th, there was short interest totaling 528,265 shares, a decrease of 42.1% from the June 15th total of 911,832 shares. Approximately 2.4% of the shares of the stock are short sold. Based on an average daily volume of 312,175 shares, the days-to-cover ratio is currently 1.7 days.

Institutional Investors Weigh In On Aardvark Therapeutics

A number of large investors have recently modified their holdings of AARD. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Aardvark Therapeutics in the second quarter valued at about $42,000. China Universal Asset Management Co. Ltd. acquired a new position in Aardvark Therapeutics during the fourth quarter worth about $47,000. Persistent Asset Partners Ltd acquired a new position in Aardvark Therapeutics during the fourth quarter worth about $56,000. New York State Common Retirement Fund purchased a new stake in Aardvark Therapeutics during the 2nd quarter valued at about $99,000. Finally, MetLife Investment Management LLC purchased a new stake in Aardvark Therapeutics during the 4th quarter valued at about $102,000.

Aardvark Therapeutics Price Performance

NASDAQ AARD opened at $6.67 on Thursday. The company has a market cap of $145.97 million, a PE ratio of -2.08 and a beta of 3.93. The stock’s 50 day simple moving average is $4.80 and its 200-day simple moving average is $7.63. Aardvark Therapeutics has a 1-year low of $3.35 and a 1-year high of $17.94.

Aardvark Therapeutics (NASDAQ:AARD) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.99) EPS for the quarter. On average, equities research analysts anticipate that Aardvark Therapeutics will post -3.46 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on AARD shares. BTIG Research cut shares of Aardvark Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 15th. Morgan Stanley restated an “underweight” rating and set a $3.00 price objective (down from $7.00) on shares of Aardvark Therapeutics in a research report on Friday, May 15th. Weiss Ratings raised shares of Aardvark Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 2nd. Finally, B. Riley Financial dropped their target price on shares of Aardvark Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Aardvark Therapeutics has a consensus rating of “Hold” and an average price target of $19.70.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.